Catalyst Pharmaceutical Screen Patients For Phase II Clinical Trial Of Meth Addiction Drug
Monday, July 07, 2008; Posted: 01:07 AM
July 7, 2008 (FinancialWire) Catalyst Pharmaceutical Partners Inc. said that it has begun enrollment for its U.S. Phase II clinical trial of a treatment for patients addicted to methamphetamine.
The development-stage pharmaceutical company said CPP-109 inhibits psychostimulant-induced dopamine release and is its version of vigabatrin, which is used to treat epilepsy and infantile spasms in some parts of the world, but is not approved for use in the U.S.
Catalyst said it expects to immediately begin screening patients for inclusion in the trial and for results to be available during the summer of 2009.
The company plans to enroll 180 methamphetamine-addicted patients at 15 treatment clinical centers in the U.S. Patients will be treated for three months, with a three-month follow-up. The goal of the study is to demonstrate that a larger proportion of CPP-109-treated subjects than placebo-treated subjects will be methamphetamine-free during their last two weeks of treatment.
Shares of Catalyst rose 46 cents to close at $3.53 Thursday. The 52-week high was $4.20 on July 19 and the 52-week low was $2.06 on November 16.